Epic Pharma, LLC received FDA approval for its ANDA040910 on July 16, 2020, to manufacture and market generic oxycodone and aspirin in oral tablets. This approval expands the manufacturer’s portfolio, further intensifying North American generic competition for this combination analgesic.